BioSpace4h
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
PipelineReview.com10h
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...
Daily11h
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
Pharmabiz13h
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Equillium stock rallies 26% on itolizumab study data
Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...